Weinberg K I, Kapoor N, Shah A J, Crooks G M, Kohn D B, Parkman R
Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, 4650 Sunset Blvd., MS#84, Los Angeles, CA 90027, USA.
Curr Allergy Asthma Rep. 2001 Sep;1(5):416-20. doi: 10.1007/s11882-001-0026-2.
Hematopoietic stem cell transplantation (HSCT) has been the definitive therapy for severe combined immune deficiency (SCID) since the first successful transplant for SCID in 1968. Improvements in the use of HSCT to treat patients with SCID are continuing. For example, during the last 5 years, the first successful in-utero HSCT, and the first success with gene therapy have occurred in patients with SCID. Debate still continues about the role of pretransplantation therapy for SCID patients, and the biology of post-HSCT immune reconstitution is under investigation.
自1968年首次成功进行重症联合免疫缺陷（SCID）移植以来，造血干细胞移植（HSCT）一直是SCID的决定性治疗方法。HSCT用于治疗SCID患者的方法仍在不断改进。例如，在过去5年中，首例成功的宫内HSCT以及首例基因治疗成功均出现在SCID患者中。关于SCID患者移植前治疗的作用仍存在争议，HSCT后免疫重建的生物学机制也正在研究中。
